3MM.F ADVICENNE (PROM.) EO-20

Healthcare Biotechnology Frankfurt Exchange
0.6530 EUR
Close of Nov 11, 2026
0.5910 2.20
Market cap
EUR 9.95M
P/E
9.3x
P/B
131.80x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 3MM.F undervalued?

Graham number

The Graham number of ADVICENNE (PROM.) EO-20 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ADVICENNE (PROM.) EO-20 fundamental analysis

No fundamental analysis for ADVICENNE (PROM.) EO-20 yet.

ADVICENNE (PROM.) EO-20 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ADVICENNE (PROM.) EO-20

Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and safe treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizur…

Full company profile